trial · primary record
Mitapivat
Sickle Cell Disease
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 286 |
| Primary completion | 2030-02 |
| Primary endpoint | Phase 2: Percentage of Participants With Hemoglobin (Hb) Response |
| Registry ID | NCT05031780 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:35.297Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05031780
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.